Osprey Medical Inc. | Income Statement

Fiscal year is January-December. All values AUD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
8.60
230.70
787.10
2,127.30
Cost of Goods Sold (COGS) incl. D&A
99.00
225.10
495.30
1,000.60
1,818.30
Gross Income
99.00
216.50
264.60
213.40
309.10
SG&A Expense
8,864.50
10,601.60
16,028.10
15,597.40
19,151.70
EBIT
8,963.50
10,818.10
16,292.70
15,810.80
18,842.60
Non Operating Income/Expense
19.60
31.00
84.30
23.90
143.80
Pretax Income
8,925.80
10,787.20
16,208.40
15,786.90
18,698.80
Income Tax
0.30
0.60
0.80
0.80
4.50
Consolidated Net Income
8,926.10
10,787.80
16,209.20
15,787.70
18,703.30
Net Income
8,926.10
10,787.80
16,209.20
15,787.70
18,703.30
Net Income After Extraordinaries
8,926.10
10,787.80
16,209.20
15,787.70
18,703.30
Net Income Available to Common
8,926.10
10,787.80
16,209.20
15,787.70
18,703.30
EPS (Basic)
0.07
0.09
0.10
0.08
0.07
Basic Shares Outstanding
123,216.80
123,879.30
154,996.70
189,706.10
284,995.60
EPS (Diluted)
0.07
0.09
0.10
0.08
0.07
Diluted Shares Outstanding
123,216.80
123,879.30
154,996.70
189,706.10
284,995.60
EBITDA
8,864.50
10,678.70
16,116.10
15,629.90
18,584.50
Non-Operating Interest Income
18.10
-
-
-
-

About Osprey Medical

View Profile
Address
5600 Rowland Road
Minnetonka Minnesota 55343
United States
Employees -
Website http://www.ospreymed.com
Updated 09/14/2018
Osprey Medical, Inc. engages in the development, and commercialization of its proprietary products for the prevention of harmful effect of X-ray dye used during commonly performed angiographic imaging procedures. Its product includes Dyevert system, which is designed to reduce the amount of dye contrast injected into the patients during standard cardiovascular procedures. The company was founded by Frank Solomon, David Kaye, and James Edward Shapland on August 31, 2005 and is headquartered in Minnetonka, MN.